Autopsy report · NCT01320020
A Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer Patients
Cause of deathNo reason given
Life of this trial
- Registered 1 month after it had already started.
- Ran for about 2 years 1 month before it stopped.
- 16 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Neovii Biotech
- Sponsor type
- Industry
- Conditions
- Epithelial Cancer Patients
- Interventions
- catumaxomab
- Participants
- 16
- Sites
- 3
- Countries
- Austria, Denmark, Spain
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.